✦ LIBER ✦

Treating bipolar depression – antidepressants and alternatives: a critical review of the literature

✍ Scribed by Antonio Tundo; Paola Cavalieri; Serena Navari; Fulvia Marchetti

Book ID: 111274202
Publisher: John Wiley and Sons
Year: 2011
Tongue: Dutch
Weight: 552 KB
Volume: 23
Category: Article
ISSN: 0924-2708
DOI: 10.1111/j.1601-5215.2011.00542.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Can antidepressants prevent interferon-a

Can antidepressants prevent interferon-alpha-induced depression? A review of the literature

✍ Amanda Galvão-de Almeida; Camila Guindalini; Susana Batista-Neves; Irismar R. de 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Treating the Physical Symptoms of Depres

Treating the Physical Symptoms of Depression With Second-Generation Antidepressants: A Systematic Review and Metaanalysis

✍ Erin E. Krebs; Bradley N. Gaynes; Gerald Gartlehner; Richard A. Hansen; Patricia 📂 Article 📅 2008 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 250 KB

Poststroke depression and functional out

Poststroke depression and functional outcome: A critical review of literature

✍ Niloufar Hadidi; Diane J. Treat-Jacobson; Ruth Lindquist 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 333 KB

The Role of Exercise in Treating Postpar

The Role of Exercise in Treating Postpartum Depression: A Review of the Literature

✍ Amanda J. Daley; Christine MacArthur; Heather Winter 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Antidepressant discontinuation manic sta

Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria

✍ Narayan, V.; Haddad, P. M. 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 162 KB

Economic appraisal of antidepressant pha

Economic appraisal of antidepressant pharmacotherapy: critical review of the literature and future directions

✍ David A. Sclar; Tracy L. Skaer; Linda M. Robison; Julie K. Stowers 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 1 views

In the United States, an estimated $44 billion is expended annually for the treatment, morbidity, and mortality associated with depression. Domestic and international cost-containment initiatives are mandating a demonstration of value for money defined in terms of a measurable health and/or financia